M&A Outlook 2012

  • 6,029 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
6,029
On Slideshare
0
From Embeds
0
Number of Embeds
3

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Thoughts:M&A Outlook 2012 Ennovance Capital LLC www.ennovance.com For queries please contact: Investment team: +1 (800) 901-1006 bd@ennovance.com
  • 2. 2011 Global Recap • M&A activity exceeded 2010 levels, but 2011 was a relatively erratic year in terms of macroeconomic factors, which contributed to market volatility ▫ European debt crisis and political indecision, Japanese earthquake/tsunami disaster, U.S. political tension, sovereign credit downgrades • 2011 saw overall growth of 9% in Global M&A volume from 2010* ▫ Accelerated activity was seen in the first half of 2011, with a slowdown toward the end of the year which resulted in a moderate year-over-year increase ▫ volume slowed during the last three quarters ▫ Financial sponsor (PE) volume was up 29% from 2010 ▫ Hostile (HF/activist shareholders) volume was down 38% from a year ago*Bloomberg. 2012 Global M&A Outlook.
  • 3. 2011 Global Recap • 2011 saw ongoing growth in in deal volume year-over-year* cross-border deal volume, with a 5.5% increase on the year* • Europe experienced a 10% boost in activity (to $875 billion) on • Large deals experienced a the year in the face of sovereign resurgence in 2011, with 145 debt issues* deals valued over $1 billion in North America* ; however, the • 2011 had a total aggregate M&A number of $10 billion deals deal volume of approximately increased from 14 to 20 in 2011 $2.15 trillion (compare to 2007 peak exceeding $4T)* • The Asia/Pacific region saw • Hostile activity of $168 billion only modest 7.7% growth in deal was down 38% in 2011 vs. a year volume * ago and represented 6% of • China continues to expand overall volume acquisitions with a 9% increase*Bloomberg. 2012 Global M&A Outlook.
  • 4. Advantages and Obstacles for 2012• The Good: ▫ More cash availability means greater deal potential ▫ Plenty of attractive targets in Europe ▫ Corporate downsizing and breakups continue ▫ Depressed valuations exist Source: Bloomberg
  • 5. Advantages and Obstacles for 2012• The Bad: European Debt as a Percentage of GDP ▫ Ongoing sovereign debt concerns Greece ▫ Lackluster economic Italy growth perpetuates uncertainty Ireland ▫ U.S. political scene is Portugal tumultuous and unpredictable, election approaching, tax code Germany questions France ▫ New and complex financial regulations UK complicate the process Spain 0% 50% 100% 150% Source: Senate Budget Committee
  • 6. Private Equity Focus• In America, private equity buyers were the most active acquirers last PE Deal Flow (United States) year, with over $138 billion in deals* ▫ Year over year, this is a more than 40% increase• Private Equity deals are growing in volume* ▫ 2011 saw seven deals announced with valuations over $5 billion, compared to only one in 2010• Plenty of divestiture in 2011 ▫ Six of the top ten PE deals last year were exits**Bloomberg. 2012 Global M&A Outlook. Source: Pitchbook
  • 7. Private Equity Focus • North America Materials and Resources (particularly the U.S.) 5% remains the top region for private equity capital flow* Financial Energy Services 7% 9% • In the U.S., PE investment Business is most prevalent in the Products and Services business products and 32% services, consumer products and Healthcare services, IT, and 12% healthcare industries** Consumer • Financial Services IT Products and experienced the greatest 13% Services reduction in PE 22% investment in 2011***Bloomberg. **Pitchbook. Private Equity Breakdown 2012. 2012 Global M&A Outlook.
  • 8. Considerations for Y2012 • The middle market is the dominant segment in private equity ▫ In the first two quarters of 2011, 75% of PE deals were valued under $250 million* ▫ Multi-billion dollar deals receive plenty of press attention, but in reality make up only a small percentage of all transactions ▫ Lending market is OK ($10+ million EBITDA) but cautious with greater financing availability for low margin, cyclical businesses ▫ Within the financial sponsor universe, nearly $500 billion of available capital and funds is beginning to expire • A massive amount of dry powder is available for investment ▫ As of October of last year, private equity firms were sitting on over $937 billion in unused capital which will need to be invested in the next several years** ▫ Some financial sponsors (PE firms) are motivated to invest, instead of returning money to their investors/LPs ▫ Strategic acquirers have been very active in the market since early 2010 as they need acquisitions to supplement organic growth and expand EPS (large cash war-chests prompting more cash deals, moderate stock deals) *Pitchbook **Bloomberg
  • 9. Considerations for Y2012 • With ongoing economic woes and market uncertainty, choice of industry is crucial to investment success ▫ Industry contraction in sectors such as financial services has left investors desiring dynamic and flexible segments to get involved in • More cross border transactions and emerging market deals ▫ Non-cyclical segments are ripe for investment for the long-term; Natural Resources, Consumer, FIG are hot ▫ Emerging markets transactions represented 26% of global M&A volume in 2011 and cross border transaction accounted for $909 billion or 35% of all M&A activity in 2011 and was up 1% from a year ago
  • 10. Considerations for Y2012 • The broader chemical industry possesses the diversity and adaptability to present potential viable opportunities in the midst of 2012’s uncertainty ▫ A host of micro-segments within the broader industry each have unique trends and attributes with links to innumerable end user applications ▫ Such a broad range of chemical sectors creates distinctive non- cyclical investment opportunities free of macroeconomic stressors • Prominent end user chemical applications are showing signs of improvement, with plenty of room for near future growth ▫ Automobiles, construction, durable goods • Activist Investors/hostile bids ▫ Trend towards increasing dialogue with shareholders in bid situations ▫ More deals likely to be played out in public
  • 11. Ennovance Capital: Chemical, chemicalrelated healthcare industry foscused privateequity investor. www.ennovance.com +1(800) 901-1006At Ennovance, we are in one business only — that ofmaking private equity investments and enhancingour portfolio companies’ value. We are not in theinvestment banking, brokerage, or advisorybusinesses; we have no alternative agendas.